培唑帕尼治疗的放射性碘难治性甲状腺癌中淋巴细胞减少与循环生物标志物动态变化同临床结局及毒性的关联:Pazothyr 试验的探索性分析
本研究基于 Pazothyr 试验探索放射性碘难治性分化型甲状腺癌(RAIR-DTC)患者中淋巴细胞减少及循环生物标志物与结局和毒性的关联。基线中度及重度淋巴细胞减少与更短的无进展生存期(PFS)相关,基线高 VEGF-A、IL-6、CXCL8 与更差 PFS 相关,高 VEGF-A、HGF、IL-6、CXCL8、CXCL9 与更短总生存期(OS)相关。培唑帕尼治疗1个月后 PlGF、HGF 等早期变化与显著治疗相关不良事件(TRAEs)相关。
要点
- 基线中度及重度淋巴细胞减少与更短 PFS 相关,高 NLR 则不然。
- 基线高 VEGF-A、IL-6、CXCL8 与更差 PFS 相关,高 VEGF-A、HGF、IL-6、CXCL8、CXCL9 与更短 OS 相关。
- 治疗1个月后 PlGF 和 HGF 升高与显著 TRAEs 独立相关。
核心结论
- 基线淋巴细胞减少和炎症血浆生物标志物与临床结局相关,而循环因子的早期变化与显著 TRAEs 相关。
- 这些探索性结果需在接受培唑帕尼或其他靶向 VEGF 受体的多激酶抑制剂治疗的 RAIR-DTC 患者中进行前瞻性验证。
- PDL1-ICS 表达对抗 PD1/PDL1 治疗的相关性需专门的前瞻性试验。
研究设计与样本
- 本研究为 Pazothyr 试验(NCT01813136)的探索性分析,评估培唑帕尼在 RAIR-DTC 患者中的疗效。
- 从 Pazothyr 临床数据库(n=168)评估淋巴细胞减少和中性粒细胞与淋巴细胞比值(NLR)。
- 额外血浆和肿瘤样本采集经专门知情同意,允许在基线及培唑帕尼治疗1个月后量化血浆血管生成因子和细胞因子(n=111)。
- 对存档原发肿瘤(n=68)进行免疫组化分析免疫标志物(CD8、FOXP3、CD163、PDL1),患者为培唑帕尼治疗6个月后应答或疾病稳定者,采用半定量评分。
- 评估与应答、无进展生存期(PFS)、总生存期(OS)和显著治疗相关不良事件(TRAEs)的关联。
主要发现
- 基线中度及重度淋巴细胞减少与更短 PFS 相关,而高 NLR 则不然。
- 基线 VEGF-A、IL-6 和 CXCL8 升高与更差 PFS 相关。
- 基线高 VEGF-A、HGF、IL-6、CXCL8 和 CXCL9 与更短 OS 相关。
- 胎盘生长因子(PlGF)、HGF、白介素12亚单位p40和 CXCL10 的早期变化与显著 TRAEs 相关。
- 多变量分析识别基线重度淋巴细胞减少(HR=2.39 [CI 1.27-4.48],p=0.007)和高 CXCL8(HR=2.01 [CI 1.26-3.21],p=0.004)为与进展相关的独立因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些探索性结果需在接受培唑帕尼或其他靶向 VEGF 受体的多激酶抑制剂治疗的 RAIR-DTC 患者中进行前瞻性验证。
- PDL1-ICS 表达对抗 PD1/PDL1 治疗的相关性需专门的前瞻性试验。
- 鉴于本研究的探索性性质,未进行多重比较校正。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pazopanib showed clinical activity in progressive radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), although its use is limited by substantial toxicity not reduced by intermittent treatment. We aimed to identify biomarkers associated with outcome and treatment-related toxicity in these patients. METHODS: This study reported exploratory results related to the Pazothyr trial (NCT01813136) investigating pazopanib efficacy in RAIR-DTC patients. We evaluated lymphopenia and neutrophil-to-lymphocyte ratio (NLR) from the Pazothyr clinical database (n = 168). Dedicated informed consent for additional plasma and tumor sample collection allowed quantification of plasma angiogenic factors and cytokines at baseline and after one month of pazopanib (n = 111). Immune markers (CD8, FOXP3, CD163, and PDL1) analyzed by immunohistochemistry in archived primary tumors from patients (n = 68) with response or stable disease after 6 months of pazopanib were scored semiquantitatively. Associations with response, progression-free survival (PFS), overall survival (OS), and substantial treatment-related adverse events (TRAEs) were evaluated. Given the exploratory nature of this study, no adjustment for multiple comparisons was performed. RESULTS: At baseline, moderate and severe lymphopenia were associated with shorter PFS, unlike high NLR. Elevated Vascular Endothelial Growth Factor A (VEGF-A), Interleukin 6 (IL-6), and CXCL8 correlated with poorer PFS. High VEGF-A, hepatocyte growth factor (HGF), IL-6, CXCL8, and CXCL9 were associated with shorter OS. X Early changes in placental growth factor (PlGF), HGF, interleukin 12 subunit p40, and CXCL10 were associated with substantial TRAEs. Multivariable analyses identified baseline severe lymphopenia (hazard ratio [HR] = 2.39 [confidence interval or CI 1.27-4.48], p = 0.007) and high CXCL8 (HR = 2.01 [CI 1.26-3.21], p = 0.004) as independent factors associated with progression. High baseline NLR (HR = 2.26 [CI 1.21-4.22], p = 0.01), HGF (HR = 2.37 [CI 1.33-4.20], p = 0.003), and CXCL8 (HR = 2.20 [CI 1.25-3.87], p = 0.006) were similarly associated with death. One-month increases in PlGF (odds ratio [OR] = 2.49 [CI 1.13-5.50], p = 0.024) and HGF (OR = 2.91 [CI 1.32-6.43], p = 0.008) were independently associated with substantial TRAEs. In patients with tumor samples, Programmed cell Death-Ligand 1 (PDL1)-immune cell score (ICS) >1% (HR = 2.05 [CI 1.15-3.66], p = 0.015) was also associated with progression. CONCLUSIONS: Baseline lymphopenia and inflammatory plasma biomarkers were associated with clinical outcome, whereas early changes in circulating factors were associated with substantial TRAEs. These exploratory results require prospective validation in RAIR-DTC patients treated with pazopanib or other VEGF receptor-targeting multikinase inhibitors. The relevance of PDL1-ICS expression for anti-PD1/PDL1-based therapies requires dedicated prospective trials.
引用
- Rodriguez C, Dalban C, Colombe-Vermorel A, et al. Lymphopenia and Circulating Biomarker Dynamics Associated with Clinical Outcome and Toxicity in Pazopanib-Treated Radioiodine-Refractory Thyroid Cancer: Exploratory Analyses from the Pazothyr Trial. Thyroid. 2026. PMID: 43007078. doi:10.1177/10507256261500974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。